MedRhythms Launches Movive™: A Breakthrough Device for Parkinson's Gait Rehabilitation

In a significant advancement in neurorehabilitation technology, MedRhythms, a pioneer in the development of music-based therapies, has announced the FDA Class II designation for its new product, Movive™. This innovative device is specifically designed to aid gait rehabilitation and enhance motor functions in adults diagnosed with Parkinson's Disease (PD).

What is Movive™?

Movive™ is an advanced neurorehabilitation system that employs the principles of Rhythmic Auditory Stimulation (RAS). According to Brian Harris, Co-Founder and CEO of MedRhythms, this device is engineered to tap into the well-documented benefits of music therapy to tackle mobility challenges faced by individuals with neurologic conditions, particularly those suffering from Parkinson's Disease. As the second product arising from MedRhythms' proprietary platform, Movive™ represents a remarkable stride towards alleviating mobility problems associated with this debilitating disease.

Parkinson's Disease is characterized by the progressive degeneration of motor functions, affecting nearly one million Americans, including a significant population of veterans. With gait impairment being one of the most common complaints reported by PD patients, Movive™ aims to provide a solution that is both accessible and effective in a patient's home environment. The device offers an engaging and personalized experience that is expected to address these significant hurdles effectively.

The Significance of FDA Class II Approval

Receiving FDA Class II designation is no small feat. This listing signifies that Movive™ has met rigorous standards for safety and effectiveness, allowing it to be marketed as a prescription-only medical device in the United States. This regulation aims to ensure that patients receive therapeutic solutions that adhere to medical safety protocols. MedRhythms hopes that the approval encourages greater uptake of music-based interventions in rehabilitation settings, thereby expanding treatment options for those affected by Parkinson's disease.

Gait Rehabilitation Made Accessible

One of the major barriers to the use of RAS has been the historical lack of accessibility. MedRhythms addresses this challenge through Movive™, designed to empower users by enabling them to engage with the therapy independently from home. By transforming therapy sessions into a more than just clinical appointment, patients can partake in rehabilitation that aligns with their routines and preferences.

The device is anticipated to hit selected markets in the U.S. by the second quarter of 2025, creating new opportunities for those striving to maintain mobility in the face of Parkinson's disease.

For more insights into the operation of Movive™ and its impact on rehabilitation, interested parties are encouraged to visit MedRhythms' official website.

About MedRhythms

Founded with the aim of revolutionizing how neurological rehabilitation is approached, MedRhythms combines proprietary technology with musical therapy to target neural pathways effectively. The company is on a mission that extends beyond Parkinson's disease, as they develop a pipeline of digital therapeutics addressing several neurological conditions including stroke and multiple sclerosis.

Notably, their prior product aimed at chronic stroke rehabilitation has already received Breakthrough Device Designation. MedRhythms recently secured a Series B financing round highlighting the growing interest in their innovative solutions.

Conclusion

As a pioneering force in the intersection of music and therapy, MedRhythms seeks to continuously improve quality of life for those contending with severe mobility challenges. The launch of Movive™ marks another step forward in achieving this mission, promising hope for many as they navigate the complexities of Parkinson's disease. MedRhythms invites the community to join them at the Association of VA Neurology Services (AVANS) Annual Meeting from March 7-9 to further explore their technological advancements and visions for the future of neurorehabilitation.